Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04558164
Recruitment Status : Recruiting
First Posted : September 22, 2020
Last Update Posted : April 15, 2022
Sponsor:
Collaborator:
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Nanthia Suthana, University of California, Los Angeles

Brief Summary:
The purpose of this study is to see if stimulation of the brain can improve memory. The investigators will use a device called transcranial magnetic stimulation that can stimulate and activate a specific part of the brain that is important for memory. The study will enroll MCI subjects who will be randomly assigned to receive active or sham brain stimulation. 'Blinded' or 'sham-controlled' means that the subject will not know whether the treatment they receive is the active treatment or the non-active stimulation. In the 'sham' condition, the stimulator will turn on but will not actually be stimulating the target brain region.

Condition or disease Intervention/treatment Phase
Cognitive Dysfunction Memory Disorders in Old Age Device: Active Theta Burst Stimulation Device: Sham Theta Burst Stimulation Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
Actual Study Start Date : January 26, 2021
Estimated Primary Completion Date : June 30, 2024
Estimated Study Completion Date : June 30, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Memory

Arm Intervention/treatment
Experimental: Active TBS
Theta burst stimulation (TBS) will be delivered at 100% of motor threshold (MT).
Device: Active Theta Burst Stimulation
Theta burst transcranial magnetic stimulation (TBS) will be delivered at 80% of motor threshold (MT).

Sham Comparator: Sham TBS
Sham stimulation will be delivered at 0% of motor threshold (MT), with all other parameters matching the active TBS condition.
Device: Sham Theta Burst Stimulation
Sham stimulation will be delivered at 10% of motor threshold (MT), with all other parameters matching the active TBS condition.




Primary Outcome Measures :
  1. Verbal recall performance change [ Time Frame: Baseline: Day 2; During stimulation: Day 3, Day 7, Day 12, Day 17; Follow-up appointments: Day 18, Day 19, Day 20. ]
    Verbal memory will be measured using a free recall task where participants learn a list of everyday words and are asked to recall as many words as they can remember after a period of distraction. Proportion of recollected words will be used to quantify memory performance changes.

  2. Object recognition memory performance change [ Time Frame: Baseline: Day 2; During stimulation: Day 3, Day 7, Day 12, Day 17; Follow-up appointments: Day 18, Day 19, Day 20. ]
    Object memory will be measured using an recognition task where participants view photos of everyday objects and are asked to identify them as OLD or NEW during a memory test wherein unseen novel objects and very similar but new photos of identical objects are shown. Recollection and discrimination index will be used to quantify memory performance changes.

  3. Associative memory performance change [ Time Frame: Baseline: Day 2; During stimulation: Day 3, Day 7, Day 12, Day 17; Follow-up appointments: Day 18, Day 19, Day 20. ]
    Associative memory will be tested using the Face Name Memory Test wherein participants are shown faces and associated names. Participants are then shown faces only and asked to recall the associated name.


Secondary Outcome Measures :
  1. Resting state fMRI functional connectivity [ Time Frame: Baseline (Day 2) before the first treatment and after the last treatment (Day 17) ]
    Resting state fMRI activity will be measured before the first and after the last TBS treatment

  2. EEG activity [ Time Frame: During treatment (Days 3, 7 and 12), and after the last treatment (Day 17) ]
    EEG functional connectivity with stimulated region and medial temporal source localized power in the theta band will be recorded during a resting period as well as during the treatment itself both before and after treatments



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 55-90 years of age
  • Right-handedness
  • Willing to provide informed consent and participate in a longitudinal study
  • In good general health
  • Ability to read, write, and speak English fluently
  • Adequate visual and auditory acuity to allow neuropsychological testing
  • Screening laboratory/ECG without abnormalities that might interfere with the study
  • Diagnosis of mild neurocognitive disorder according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) criteria
  • Living independently
  • Subjective memory complaints (self-report and positive score on MFQ)
  • Katz ADL scale: We will exclude potential volunteers scoring < 6
  • Lawton iADL scale: We will exclude potential volunteers scoring < 8 (however, having points off is OK if the volunteer never did a task even prior to memory loss (e.g., more men than women never shopped, did laundry, or cooked due to stereotypical social roles). In such an example, the volunteer could score as low as 5 and still be included (no points off for the three activities never done before memory loss).
  • MMSE score > 24
  • PHQ score > 7
  • Hamilton Depression score < 7
  • No change in use of psychotropic medication for treatment of depression, anxiety, ADHD or psychosis 1 month prior and during the study.
  • At least 1 Standard Deviation below the mean in 2 out of the 3 following tests: BVMT-R (25-minute delay), CVLT-II (20-minute delay), Rey-Osterrieth Complex Figure Task (30-minute delay).

Exclusion Criteria:

  • Diagnosis of dementia
  • Unwilling or unable to provide informed consent
  • Active major psychiatric or neurologic disorders associated with neurocognitive impairment
  • Active or history of alcohol or substance abuse
  • Recent (< 6 months) alcohol or substance abuse excluding nicotine or caffeine
  • Active or history of stroke, traumatic brain injury with loss of consciousness, or other neurologic disorder (e.g., Epilepsy, Huntington's disease, Parkinson's disease)
  • Non-English speaking participants
  • Not right handed based on self-report or evaluation based on a standard report
  • Has received TMS before (not TMS naïve)
  • Head trauma or systemic diseases affecting brain function
  • Sleep deprivation
  • Uncontrolled hypertension or cardiovascular disease
  • is taking:

    • anticholinergic medication (e.g., Detrol, Cogentin);
    • sedating antihistamine (e.g., Benadryl);
    • any drug that has significant anticholinergic or antihistaminic side effects (e.g., tricyclic antidepressant medications, Remeron).
    • Benzodiazepines. While not a strict rule out, this will be decided on a case-by-case basis depending on the dose.
  • Current enrollment in a memory-enhancement study or course
  • Contraindication to the MRI including claustrophobia, metal in body, surgery within 60 days, certain implants or previous abnormal MRI results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04558164


Contacts
Layout table for location contacts
Contact: Sonja Hiller 3107947517 suthanalab@mednet.ucla.edu

Locations
Layout table for location information
United States, California
University of California Los Angeles Recruiting
Los Angeles, California, United States, 90024
Contact: Sonja Hiller    310-794-7517    shiller@mednet.ucla.edu   
Sponsors and Collaborators
University of California, Los Angeles
National Institute on Aging (NIA)
Investigators
Layout table for investigator information
Principal Investigator: Nanthia Suthana University of California, Los Angeles
Layout table for additonal information
Responsible Party: Nanthia Suthana, Principal Investigator, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT04558164    
Other Study ID Numbers: 20-001417
R01AG068317 ( U.S. NIH Grant/Contract )
First Posted: September 22, 2020    Key Record Dates
Last Update Posted: April 15, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The data collected for this research represent a valuable resource to the scientific community, and the PIs will make them accessible to others, while respecting the special needs for confidentiality. All data will be anonymized before being provided to the scientific community. Researchers can also request access to the data under collaborative and co-authorship agreements prior to the end of the funding period or before publication. The results from the proposed project will also be shared at scientific meetings (local, national and international) as well via published manuscripts.
Time Frame: All data will be provided by the time publication occurs or when the proposed funding period has ended.
Access Criteria: Researchers can request access to the data under collaborative and co-authorship agreements prior to the end of the funding period or before publication.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Memory Disorders
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases